CRIS2Curis, Inc. (NASDAQ:CRIS) announced the appointment of Lori A. Kunkel, M.D. to its Board of Directors.

Dr. Kunkel currently serves on the Board of Directors at Loxo Oncology, where she was formerly Acting Chief Medical Officer.  Prior to Loxo Oncology, Dr. Kunkel served as Chief Medical Officer at Pharmacyclics, Inc. leading integrated clinical development highlighted by the approval of IMBRUVICA®. She has also served as Chief Medical Officer at Proteolix Inc. (acquired by Onyx), Syndax, and ACT Biotech.

Prior to joining the biotechnology industry in 1995, Dr. Kunkel spent ten years in academic/clinical medicine and served as a faculty member in the Division of Hematology/Oncology’s Bone Marrow Transplant Unit at University of California, Los Angeles.

She trained in internal medicine at Baylor College of Medicine, hematology at USC and oncology at UCLA, earning board certifications in these specialties.

“We are delighted to welcome Lori to the Board of Curis and we will benefit tremendously from her depth of experience and instincts as we develop our drug candidates and place the company on a path for approval and commercialization of our products,” said CEO Ali Fattaey.  “Lori is well known and respected in the biotechnology community and we have benefited from her role as an advisor to the company in the past.”

“I am pleased to join the Curis Board and look forward to working closely with the Board and management team as we collectively advance Curis as a leading oncology company,” said Dr. Kunkel. (Original Source)

Shares of Curis closed last Friday at $3.36, up $0.12 or 3.70%. CRIS has a 1-year high of $3.49 and a 1-year low of $1.25. The stock’s 50-day moving average is $2.81 and its 200-day moving average is $1.91.

On the ratings front, Curis has been the subject of a number of recent research reports. In a report issued on October 12, RBC analyst Adnan Butt reiterated a Buy rating on CRIS, with a price target of $7, which implies an upside of 108% from current levels. Separately, on September 7, Robert W. Baird’s Brian Skorney reiterated a Buy rating on the stock and has a price target of $7.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Adnan Butt and Brian Skorney have a yearly average loss of 2.2% and a return of 4.7% respectively. Butt has a success rate of 45% and is ranked #3401 out of 4209 analysts, while Skorney has a success rate of 48% and is ranked #706.

Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Its pipeline includes is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase, or HDAC, and phosphatidylinositol-3-kinase, or PI3K enzymes. The company conducts research programs both internally and through strategic collaborations. Curis was founded on February 14, 2000 and is headquartered in Lexington, MA.